Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Lantheus appoints Amanda Morgan SVP, commercial » 08:19
11/29/22
11/29
08:19
11/29/22
08:19
LNTH

Lantheus

$60.89 /

+2.49 (+4.26%)

, ACAD

Acadia Pharmaceuticals

$14.78 /

-0.315 (-2.09%)

Lantheus Holdings (LNTH)…

Lantheus Holdings (LNTH) announced the appointment of Amanda Morgan as Senior Vice President, Commercial. Ms. Morgan will report to Paul Blanchfield, Lantheus' COO, and will be responsible for leading all of the Company's commercial activities, including Sales, Marketing, and Market Access. She was most recently the Chief Revenue and Customer Officer at Acadia Pharmaceuticals (ACAD) where she led the commercial organization.

ShowHide Related Items >><<
LNTH Lantheus
$60.89 /

+2.49 (+4.26%)

ACAD Acadia Pharmaceuticals
$14.78 /

-0.315 (-2.09%)

LNTH Lantheus
$60.89 /

+2.49 (+4.26%)

11/15/22 Truist
Point Biopharma price target lowered to $14 from $22 at Truist
11/14/22 Piper Sandler
Point Biopharma price target lowered to $14 from $17 at Piper Sandler
10/12/22 Mizuho
Lantheus initiated with a Buy at Mizuho
10/06/22 JonesTrading
Lantheus initiated with a Buy at JonesTrading
ACAD Acadia Pharmaceuticals
$14.78 /

-0.315 (-2.09%)

11/14/22 JPMorgan
Acadia Pharmaceuticals price target lowered to $17 from $19 at JPMorgan
11/03/22 Goldman Sachs
Acadia Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
11/01/22 Loop Capital
Acadia Pharmaceuticals initiated with a Hold at Loop Capital
10/07/22 Mizuho
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho
LNTH Lantheus
$60.89 /

+2.49 (+4.26%)

ACAD Acadia Pharmaceuticals
$14.78 /

-0.315 (-2.09%)

LNTH Lantheus
$60.89 /

+2.49 (+4.26%)

ACAD Acadia Pharmaceuticals
$14.78 /

-0.315 (-2.09%)

ACAD Acadia Pharmaceuticals
$14.78 /

-0.315 (-2.09%)

Over a week ago
Recommendations
Acadia Pharmaceuticals price target lowered to $17 from $19 at JPMorgan » 07:52
11/14/22
11/14
07:52
11/14/22
07:52
ACAD

Acadia Pharmaceuticals

$16.39 /

-0.005 (-0.03%)

JPMorgan analyst Tessa…

JPMorgan analyst Tessa Romero lowered the firm's price target on Acadia Pharmaceuticals to $17 from $19 and keeps an Overweight rating on the shares. The analyst sees Acadia "working through a period of reset." For the legacy business of Nuplazid in Parkinson's disease psychosis, Romero sees a "somewhat challenged overall outlook." Romero believes trofinetide for the treatment of the rare neurodevelopmental disorder, Rett Syndrome, likely represents the second approved drug for Acadia with its March 12, 2023 FDA action date. However, she expects a "more gradual ramp for the product as the market is built."

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$16.39 /

-0.005 (-0.03%)

ACAD Acadia Pharmaceuticals
$16.39 /

-0.005 (-0.03%)

11/03/22 Goldman Sachs
Acadia Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
11/01/22 Loop Capital
Acadia Pharmaceuticals initiated with a Hold at Loop Capital
10/07/22 Mizuho
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho
09/13/22 Guggenheim
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
ACAD Acadia Pharmaceuticals
$16.39 /

-0.005 (-0.03%)

ACAD Acadia Pharmaceuticals
$16.39 /

-0.005 (-0.03%)

ACAD Acadia Pharmaceuticals
$16.39 /

-0.005 (-0.03%)

Over a month ago
Downgrade
Acadia Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs » 19:21
11/03/22
11/03
19:21
11/03/22
19:21
ACAD

Acadia Pharmaceuticals

$14.81 /

-1.125 (-7.06%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter downgraded Acadia Pharmaceuticals to Sell from Neutral with a price target of $12, down from $15. The company's Q3 Nuplazid revenue was below consensus, and it faces a challenging forward outlook due to unfavorable channel dynamics and pricing constraints due to the recently passed Inflation Reduction Act which has historically been a key lever for Nuplazid sales growth, the analyst tells investors in a research note. Richter adds however that she continues to monitor Acadia's pipeline and sees a potentially notable opportunity for trofinetide in Rett syndrom.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$14.81 /

-1.125 (-7.06%)

ACAD Acadia Pharmaceuticals
$14.81 /

-1.125 (-7.06%)

11/01/22 Loop Capital
Acadia Pharmaceuticals initiated with a Hold at Loop Capital
10/07/22 Mizuho
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho
09/13/22 Guggenheim
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
ACAD Acadia Pharmaceuticals
$14.81 /

-1.125 (-7.06%)

ACAD Acadia Pharmaceuticals
$14.81 /

-1.125 (-7.06%)

ACAD Acadia Pharmaceuticals
$14.81 /

-1.125 (-7.06%)

Earnings
Acadia Pharmaceuticals cuts FY21 NUPLAZID net sales guidance to $510M-$520M » 16:33
11/02/22
11/02
16:33
11/02/22
16:33
ACAD

Acadia Pharmaceuticals

$15.94 /

+0.06 (+0.38%)

Prior guidance was…

Prior guidance was $510M-$540M. Consensus $530.7M.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

11/01/22 Loop Capital
Acadia Pharmaceuticals initiated with a Hold at Loop Capital
10/07/22 Mizuho
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho
09/13/22 Guggenheim
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

Earnings
Acadia Pharmaceuticals reports Q3 EPS (17c), consensus (19c) » 16:32
11/02/22
11/02
16:32
11/02/22
16:32
ACAD

Acadia Pharmaceuticals

$15.94 /

+0.06 (+0.38%)

Reports Q3 revenue…

Reports Q3 revenue $130.7M, consensus $138.8M. "Our third quarter results reflect continued growth in demand for NUPLAZID, driven by early signs of improvement in the long-term care channel," said Steve Davis, Chief Executive Officer. "In the quarter we announced that our new drug application of trofinetide for the treatment of Rett syndrome has been accepted for filing by the FDA and granted a priority review. Furthermore, we continued to advance our late and early-stage portfolio, including our Phase 3 program for pimavanserin for the treatment of the negative symptoms of schizophrenia and our Phase 1 ACP-204 program for neuropsychiatric indications."

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

11/01/22 Loop Capital
Acadia Pharmaceuticals initiated with a Hold at Loop Capital
10/07/22 Mizuho
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho
09/13/22 Guggenheim
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

ACAD Acadia Pharmaceuticals
$15.94 /

+0.06 (+0.38%)

Initiation
Acadia Pharmaceuticals initiated with a Hold at Loop Capital » 06:14
11/01/22
11/01
06:14
11/01/22
06:14
ACAD

Acadia Pharmaceuticals

$16.04 /

-0.09 (-0.56%)

Loop Capital analyst…

Loop Capital analyst Esther Hong initiated coverage of Acadia Pharmaceuticals with a Hold rating and $17 price target. Acadia is focused on the treatment of central nervous system disorders and it has one product on the market, Nuplazid, which is the only FDA-approved therapy for Parkinson's disease psychosis, Hong tells investors in a research note. The analyst believes Acadia has a potentially attractive pipeline longer-term, but remains on the sidelines given the lack of meaningful near-term catalysts.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$16.04 /

-0.09 (-0.56%)

ACAD Acadia Pharmaceuticals
$16.04 /

-0.09 (-0.56%)

10/07/22 Mizuho
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho
09/13/22 Guggenheim
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
08/09/22 Morgan Stanley
Acadia Pharmaceuticals price target lowered to $18 from $22 at Morgan Stanley
ACAD Acadia Pharmaceuticals
$16.04 /

-0.09 (-0.56%)

ACAD Acadia Pharmaceuticals
$16.04 /

-0.09 (-0.56%)

ACAD Acadia Pharmaceuticals
$16.04 /

-0.09 (-0.56%)

Recommendations
Acadia Pharmaceuticals price target lowered to $17 from $19 at Mizuho » 06:46
10/07/22
10/07
06:46
10/07/22
06:46
ACAD

Acadia Pharmaceuticals

$18.62 /

+0.59 (+3.27%)

Mizuho analyst Uy Ear…

Mizuho analyst Uy Ear lowered the firm's price target on Acadia Pharmaceuticals to $17 from $19 and keeps a Neutral rating on the shares. The analyst cites primarily lower sales forecasts for Nuplazid in Parkinson's disease dementia for the target drop. Given the ongoing challenges in Parkinson's disease market, and the Inflation Reduction Act restricting price increases to the inflation rate going forward, the consensus sales forecasts are likely too high and may need downward revision, Ear tells investors in a research note.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$18.62 /

+0.59 (+3.27%)

ACAD Acadia Pharmaceuticals
$18.62 /

+0.59 (+3.27%)

09/13/22 Guggenheim
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
08/09/22 Morgan Stanley
Acadia Pharmaceuticals price target lowered to $18 from $22 at Morgan Stanley
08/09/22 RBC Capital
Acadia Pharmaceuticals price target lowered to $21 from $26 at RBC Capital
ACAD Acadia Pharmaceuticals
$18.62 /

+0.59 (+3.27%)

ACAD Acadia Pharmaceuticals
$18.62 /

+0.59 (+3.27%)

ACAD Acadia Pharmaceuticals
$18.62 /

+0.59 (+3.27%)

Recommendations
FDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim » 08:49
09/13/22
09/13
08:49
09/13/22
08:49
ACAD

Acadia Pharmaceuticals

$17.91 /

+0.505 (+2.90%)

After Acadia announced…

After Acadia announced that the FDA has accepted the NDA of trofinetide for the treatment of Rett syndrome, granted the application priority review and said that at this time the agency is not planning to hold an Advisory Committee meeting, Guggenheim analyst Yatin Suneja said the lack of an AdCom is "a positive sign for the likelihood of approval." The impact of trofinetide's tolerability profile may affect the overall addressable market for the drug, but Suneja doesn't think it will impact potential approval given the significant unmet need and the analyst currently models $675M in peak sales for trofinetide. Suneja has a Neutral rating on Acadia Pharmaceuticals shares with no price target.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$17.91 /

+0.505 (+2.90%)

ACAD Acadia Pharmaceuticals
$17.91 /

+0.505 (+2.90%)

08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
08/09/22 Morgan Stanley
Acadia Pharmaceuticals price target lowered to $18 from $22 at Morgan Stanley
08/09/22 RBC Capital
Acadia Pharmaceuticals price target lowered to $21 from $26 at RBC Capital
08/09/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
ACAD Acadia Pharmaceuticals
$17.91 /

+0.505 (+2.90%)

ACAD Acadia Pharmaceuticals
$17.91 /

+0.505 (+2.90%)

ACAD Acadia Pharmaceuticals
$17.91 /

+0.505 (+2.90%)

Hot Stocks
Acadia Pharmaceuticals files trofinetide NDA » 07:32
09/12/22
09/12
07:32
09/12/22
07:32
ACAD

Acadia Pharmaceuticals

$17.40 /

-0.015 (-0.09%)

Acadia Pharmaceuticals…

Acadia Pharmaceuticals announced that the FDA has accepted for filing its new drug application, or NDA, of trofinetide for the treatment of Rett syndrome. The FDA has granted a priority review and assigned a PDUFA action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$17.40 /

-0.015 (-0.09%)

ACAD Acadia Pharmaceuticals
$17.40 /

-0.015 (-0.09%)

08/10/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
08/09/22 Morgan Stanley
Acadia Pharmaceuticals price target lowered to $18 from $22 at Morgan Stanley
08/09/22 RBC Capital
Acadia Pharmaceuticals price target lowered to $21 from $26 at RBC Capital
08/09/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
ACAD Acadia Pharmaceuticals
$17.40 /

-0.015 (-0.09%)

ACAD Acadia Pharmaceuticals
$17.40 /

-0.015 (-0.09%)

ACAD Acadia Pharmaceuticals
$17.40 /

-0.015 (-0.09%)

Over a quarter ago
Recommendations
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho » 06:49
08/10/22
08/10
06:49
08/10/22
06:49
ACAD

Acadia Pharmaceuticals

$16.23 /

-0.44 (-2.64%)

Mizuho analyst Uy Ear…

Mizuho analyst Uy Ear lowered the firm's price target on Acadia Pharmaceuticals to $19 from $27 and keeps a Neutral rating on the shares post the Q2 results. Management lowered 2022 sales guidance modestly at the midpoint, as recovery in the Parkinson's disease psychosis market remained slower than expected, Ear tells investors in a research note.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$16.23 /

-0.44 (-2.64%)

ACAD Acadia Pharmaceuticals
$16.23 /

-0.44 (-2.64%)

08/09/22 Morgan Stanley
Acadia Pharmaceuticals price target lowered to $18 from $22 at Morgan Stanley
08/09/22 RBC Capital
Acadia Pharmaceuticals price target lowered to $21 from $26 at RBC Capital
08/09/22 Mizuho
Acadia Pharmaceuticals price target lowered to $19 from $27 at Mizuho
08/09/22 H.C. Wainwright
Acadia Pharmaceuticals price target raised to $25 from $20 at H.C. Wainwright
ACAD Acadia Pharmaceuticals
$16.23 /

-0.44 (-2.64%)

ACAD Acadia Pharmaceuticals
$16.23 /

-0.44 (-2.64%)

ACAD Acadia Pharmaceuticals
$16.23 /

-0.44 (-2.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.